Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.42 |
| ▸ | INSR | P06213 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858185 | 1.00 | KDR (0.57) | KDRALDH1A1LMNAL3MBTL1ALK | |
| SCHEMBL6855224 | 0.73 | KDR (1.00) | KDRLMNAALKINSR | |
| SCHEMBL6859348 | 0.68 | KDR (0.63) | KDRALDH1A1LMNAALKINSR | |
| SCHEMBL6859343 | 0.68 | KDR (0.63) | KDRALDH1A1LMNAALKINSR | |
| SCHEMBL8814028 | 0.67 | ALDH1A1 (0.67) | KDRALDH1A1LMNAL3MBTL1ALK | |
| SCHEMBL6855227 | 0.67 | KDR (0.56) | KDRALKINSRSMN1; SMN2 | |
| SCHEMBL6855231 | 0.67 | KDR (0.56) | KDRALKINSRSMN1; SMN2 | |
| SCHEMBL4861456 | 0.66 | LMNA (0.60) | ALDH1A1LMNAL3MBTL1ALK | |
| SCHEMBL4861458 | 0.66 | LMNA (0.60) | ALDH1A1LMNAL3MBTL1ALK | |
| SCHEMBL21777545 | 0.66 | ALDH1A1 (0.58) | ALDH1A1LMNAL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831075-B2 | Administering to a host for inhibiting kinase activity a 5-heterocylcic subustituted pyrazolone derivative | CEPHALON, INC. | 2004-12-14 | — | — | US | disclosed |
| US-20030162775-A1 | Heterocyclic substituted pyrazolones | CEPHALON, INC. | 2003-08-28 | — | — | US | disclosed |
| US-6455525-B1 | Heterocyclic substituted pyrazolones | CEPHALON, INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1226141-A1 | HETEROCYCLIC SUBSTITUTED PYRAZOLONES | CEPHALON, INC. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001032653-A1 | HETEROCYCLIC SUBSTITUTED PYRAZOLONES | CEPHALON, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162775-A1 | Heterocyclic substituted pyrazolones | CYP3A4, CYP3A5, PDXK | KDR 3412/4885ALDH1A1 212/4885LMNA 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.